Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | BPTF | Q12830 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957583 | 0.78 | HTR7 (0.48) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL12635642 | 0.77 | ADK (0.41) | — | |
| SCHEMBL2955161 | 0.77 | HTR7 (0.47) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL1580030 | 0.75 | SLC6A2 (0.52) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL1880939 | 0.75 | BPTF (0.58) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL1579254 | 0.74 | BPTF (0.43) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL1579251 | 0.74 | BPTF (0.43) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL1579440 | 0.74 | BPTF (0.43) | ADRB1BPTFADRB2HTR7HTR1A | |
| SCHEMBL1579592 | 0.72 | PRMT5 (0.45) | ADRB1BPTFHTR1AHTR2CHTR6 | |
| SCHEMBL1877422 | 0.72 | BPTF (0.44) | ADRB1BPTFADRB2HTR3AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102159554-B | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| EP-2310374-B1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-31 | — | — | EP | disclosed |
| CN-102159554-A | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2011-08-17 | — | — | CN | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| EP-2310374-A1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010000456-A1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | HTR6, HTR5A, HTR1A | ADRB1 112/4885BPTF 2547/4885ADRB2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.